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Abstract
  
	 It	has	been	known	that	there	are	differences	in	response	to	medications	both	in	
terms	of	clinical	activity	and	side	effects.	Among	all	influencing	factors,	genetic	variation	
has	been	considered	to	play	a	crucial	part.	By	genetic	investigation,	the	differences	in	
drug	metabolism,	transport	and	target	could	be	disclosed.	Termed	as	“pharmacogenetics	
(PGx)”,	that	focuses	on	the	variants	within	one	or	more	candidate	genes.	Genetic	tests	
have	 been	 started	 for	 screening	 polymorphisms	prior	 to	 drug	 prescription,	moreover	
many	 biomarkers	 were	 developed	 in	 oncology.	 Recent	 PGx	 investigations	 have	 been	
conducted	to	identify	mRNAs,	microRNAs	(miRNAs)	and	other	downstream	signals	that	
are	affected	by	variation	in	genes	that	might	cause	drug	response	variability.	Another	
intriguing	study	related	to	PGx	in	cancer	stem	cells	(CSCs)	has	recently	aroused.	CSC	
shows	more	resistant	behavior	to	drug.	CSCs	are	subpopulation	of	cells,	which	share	some	
same	markers	with	stem	cells.	CSC	can	 induce	specific	signal	transduction	pathways.	
Variation	in	genes	affect	CSCs	activity	are	generally	neglected	in	the	past	PGx	studies.	
This	could	be	one	of	the	explanation	why	past	PGx	studies	in	cancer	cell	do	not	achieve	
optimalclinical	outcome.
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INTRODUCTION
 Age, race/ethnicity, weight, gender, 
concomitant diseases and drugs, social factors and 
genetics and many others can affect drug response. 
Among these factors, variation in genes plays 
important role in the variation in drug response. 
Pharmacogenetics (PGx) studies have been 
trying to correlate genetic variability with human 
drug response variability. Since understanding 
in association of genes with diseases and drug 
responses getting improved, clinical genetic tests 
may emerge to enrich conventional methods of 
assessing drug responses and diseases.
 Recent PGx investigations have been started to 
identify mRNAs, microRNAs (miRNAs) and other 
downstream signals that are affected by variation 
in genes. These that might cause drug response 
variability. Although thousand genomes have been 
sequenced, the task is still remained to transform 
the information for the purpose of personal health 
identification as well as personalized treatment 
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strategies. Since there is patient-to-patient 
variation in drug response, the treatment can't be 
generalized. The treatment should be tailored based 
on the detected unique genes of each individu. 
With personalized treatment, the benefit can be 
maximized, while the risk of adverse side effects 
can be minimized (Madian, et al., 2012).
PGx 
 Age, Genes that cause differences in drug 
response is correlated with variation in genes 
involved in the drug pharmacokinetics including 
the absorbance, metabolization, distribution, and 
excretion. Besides the drug pharmacokinetics, the 
drug pharmacodynamics including drug-target 
interaction and mechanism of action, are also 
correlated (Salari, et al., 2012). Single nucleotide 
polymorphisms (SNPs) can now be genotyped 
at high  thoughput  and  relatively  affordable. 
Therefore, characterization of novel polymorphisms 
and rare mutations should be pursued (Madian, et 
al., 2012).
 PGx have been widely conducted in oncology.
Expression of somatic genetic changes in tumor 
can markedly elevate or decrease compared with 
normal tissue (Salari, et al., 2012). Therefore, 
genetic analysis of tumor gene expression can 
provide information of therapeutic target, i.e., 
Human Epidermal Receptor 2 (HER2) in breast 
cancers, epidermal growth factor receptor (EGFR) 
in lung cancers, Philadelphia chromosome in 
chronic myelogenous leukaemias (Salari, et al., 
2012). Mutations in tumors can be used to anticipate 
resistance of targeted drug, for example in colorectal 
cancers, the V-Kiras2 Kirsten rat sarcoma viral 
oncogene homolog (KRAS) mutations can be used 
to approach the use of cetuximab and panitumumab 
as EGFR-specific antibodies/targeted drug (Salari, 
et al., 2012; Amado, et al., 2008; Karapetis, et al., 
2008; van Cutsem, et al., 2009).
 In cardiovascular, warfarin dose varies by 
over 10-fold, meanwhile the therapeutic window 
is narrow. The variation is related with 3 variants 
in cytochrome P450, family 4, subfamily F, 
polypeptide 2 (CYP4F2), CYP2C9, and vitamin K 
epoxide reductase complex, subunit 1 (VKORC1).
(Salari, et al., 2012; Caldwell, et al., 2008; Rieder, 
et al., 2005; Sconce, et al., 2005; Takahashi, et al., 
2006).
miRNA IN PGx
 miRNA is a small non-coding RNAs. miRNA 
conserves of 21-25 nucleotides in length. miRNA 
has been reported to be able to down-regulate gene 
expression gene expression at the level of post-
transcription (Zhang and Dolan, 2010). Not only 
in mammals, miRNAs can be found in genomes of 
plants, worms and flies (Zhang and Dolan, 2010; 
Lee, et al., 2007). More than 700 miRNAs have 
been identified in humans based on experimental 
research and bioinformatic study (Zhang and Dolan, 
2010; Griffiths-Jones, et al., 2008).
 miRNAs play important roles in gene 
expression regulatory. miRNA binds to the 3’ 
untranslated regions (3'UTRs) of the gene traget 
and reduces gene expression at the level of post-
transcription.(Zhang and Dolan, 2010; He and 
Gregory, 2004) miRNAs have been reported to be 
correlated with various cancers, including leukemia 
(Garzon, et al., 2008), prostate cancer (Ambs, et 
al., 2008), gastric cancer (Ueda, et al., 2010), lung 
cancer (Wu, et al., 2009), breast cancer (Khoshnaw, 
et al., 2009), and liver cancer (Mott, et al., 2009). 
miRNAs could affect the cancer in the initiation and 
progression stages (Garzon, et al., 2009). miRNAs 
have been reported to invove in prognosis of cancer 
as well. Not only exixtence of miRNAs, but its 
alteration is also correlated with various cancers 
(Garzon, et al., 2009).
 miRNAs may also contribute to drug 
response, for example through regulating key drug 
metabolizing genes such as CYP. For example, 
the escape of miR-519c by 3'UTR truncation was 
found to enable drug-resistant cells to maintain high 
expression of ATP-binding cassette (ABC), sub-
family G, member 2 (ABCG2), a transporter that is
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related to the absorption, distribution and excretion 
of drugs and cytotoxins (To, et al., 2009; Zhang and 
Dolan, 2010).
 miR-451 and miR-27a were found to increase 
the expression of P-glycoprotein, ABC, sub-
family B, member 1 (ABCB1) gene product that 
affect cancer cells resistance to a broad range 
of chemotherapeutic agents (Zhu, et al., 2008) 
Particularly, the expressions of miR-451 and miR-
27a are up-regulated in some multidrug resistant 
cancer cell lines, as compared with their parental 
lines.(22) In another study, a SNP of miR-146a 
precursor was demonstrated to affect its binding to 
the 3'UTRs of breast cancer 1, early onset (BRCA1) 
as well as BRCA2 mRNAs, thus potentially 
modulating their expression.(Zhang and Dolan, 
2010; Shen, et al., 2008).
CSC IN PGx
 Identified based on surface markers, enzymatic 
activity, or drug-efflux transporters, CSCs can form 
tumor when injected into immunologically deficient 
mice (Bonnet and Dick, 1997). Based on cell type 
and marker, frequency of CSCs can be found ~20% 
(Crea, et al., 2011) CSC can be specified by key 
signaling pathways. The signaling pathway is 
composed by a definite group of genes. Wnt, Notch 
and Hedgehog have been reported as the principal 
signaling pathways of CSC selfrenewal (Crea, et 
al., 2011). There are CSC-specific pathways that 
contribute to CSC drug resistance (Crea, et al., 
2011). Hedgehog pathway has been reported to 
play important role in the maintenance of CSCs 
(Crea, et al., 2011). For example, proliferation and 
survival of CD133+ glioma CSCs were shown 
relied on Hedgehog pathway (Clement, et al., 2007; 
Ehtesham, et al., 2007) Major signaling pathways 
in normal stem cells regulating proliferation and 
differentiation were also shown to be the key player 
in CSCs. These pathways could be suggested as the 
target for CSC eradication (Crea, et al., 2011) or 
CSC reprogram (Wijaya, et al., 2011).
 Expression of CD133 was reported to be 
correlated with poor survival in colorectal cancer 
(Artells, et al., 2010) and glioblastoma (Pallini, et 
al., 2008). Expression of CD133 was also correlated
with expression of drug resistance genes in non-
small cell lung cancer (NSCLC) (Salnikov, et 
al., 2010). In addition, CD133 was reported to be 
correlated with premalignancy in oral tissue (Amtha, 
et al., 2015). Meanwhile CD44 expression was 
reported to be correlated with the risk of metastasis 
in gastric (Okayama, et al., 2009) and breast cancers 
(Celebiler Cavusoglu, et al., 2009). All disclosed 
gene expression profiles of CSCrelated pathways are 
useful for future pharmacogenomicdevelopment.
CONCLUSION
 PGx studies in miRNAs and CSCs have 
enriched personalized treatment strategies, so 
that each individual could have tailored treatment 
in attempts to maximize therapeutic benefit and 
minimize side effects. Therefore earlier PGx 
studies those correlating genetic variability with 
human drug response variability should be added 
with miRNAs which play important regulatory 
roles in gene expression, and CSCs markers which 
are highly related with drug resistance and poor 
survival.
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